Start here if you're new
what it is
Vor Biopharma builds cell and gene therapies for acute myeloid leukemia, a blood cancer that hits about 20,000 new U.S. patients a year.
how it gets paid
Last year Vor Biopharma made n/a in revenue.
what just happened
Latest-quarter EPS was -$378.11, and the company still had no reported revenue.
At a glance
B balance sheet — gets the job done, barely
-$34.00 fy2024 eps est
1.6 beta
~$561M market cap
small cap
xvary composite: 34/100 — weak
What they do
Vor Biopharma builds cell and gene therapies for acute myeloid leukemia, a blood cancer that hits about 20,000 new U.S. patients a year.
It is trying to shield healthy donor cells from on-target toxicities, which means the treatment can keep the good cells and dodge the bad ones. That is a weirdly elegant fix for a disease this brutal. AML affects about 20,000 new U.S. patients each year, so your upside sits in a small but serious market.
How they make money
n/a
annual revenue
The products that matter
lead cell therapy candidate
VOR33
Phase 1/2a · lead program
This is the only clinical-stage asset shown here, which means the current $561M market value is mostly a judgment on one program's odds.
pipeline
CD33-edited stem cell platform
tumor-targeted therapy platform
0% gross margin
The platform may be scientifically interesting, but 0% gross margin and $0 revenue tell you it is still a lab-stage asset, not an operating business.
platform bet
Key numbers
$13.17
share price
You are paying a real stock price for a company with no reported revenue, which is the whole gamble.
$561M
market cap
That is the value the market assigns before the science proves itself.
-$34.00
FY2024 EPS
This is the loss per share for the year, which means each share carried a heavy burn.
$3M
debt
Low debt helps, but it does not replace revenue when the company is still burning cash.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $3M (0% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for VOR right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Latest-quarter EPS was -$378.11, and the company still had no reported revenue.
EDGAR shows no annual revenue, and Yahoo reports TTM revenue at $0M. That means the loss is still the story, not sales growth.
$0M
revenue
-$378.11
eps
n/a
n/a
the number that mattered
The -$378.11 EPS print mattered because there is no sales base to soften the blow.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk is VOR33 failing to prove the platform works in humans. This is a one-program story until the data say otherwise.
med
VOR33 data disappoint
The lead asset is in Phase 1/2a and there is no approved backup engine generating revenue. If the trial undermines the CD33 thesis, the market is left valuing $0 revenue science with fewer reasons to be patient.
Impact: it threatens the core rationale behind the current $561M valuation.
med
cash burn outruns clinical progress
Q3 2025 produced a $28.9M net loss, revenue remains $0, and the company needed a $100M raise in November 2025. That is normal for biotech. It is still dilution risk if the data timeline stretches.
Impact: more capital raises can pressure the stock before the science has earned a higher valuation.
med
the shareholder base is crowded with institutions
97.29% institutional ownership sounds comforting until those same holders decide the readout is late, weak, or not worth waiting for. When nearly the whole float is professional money, exits can get crowded.
Impact: volatility can spike around data, financing, or any sign that conviction is slipping.
With $0 revenue, the downside is not a bad quarter. It is a broken thesis, more dilution, or both.
source: institutional data · regulatory filings · risk analysis
Pay attention to
clinical catalyst
the next VOR33 data update
This is the event that matters. A Phase 1/2a stock with $0 revenue does not get rerated on accounting. It gets rerated on human data.
cash burn
how quickly the $100M raise gets consumed
Watch each quarterly loss against the November 2025 financing. In pre-revenue biotech, runway is strategy wearing accounting clothes.
share supply
post-lock-up trading pressure
The 9-feb-2026 lock-up end does not change intrinsic value, but it can change short-term price behavior. On a stock this volatile, that still matters.
street sentiment
whether the $32–$55 target band holds
Analysts currently span $32 to $55 with a $46 average target. If that range starts moving down after data or financing updates, pay attention.
Analyst rankings
risk profile
below average
risk rank 4 — more volatile than most — brace for bigger swings.
chart momentum
bottom 5%
momentum rank 5 — the lowest rating — significant underperformance expected.
source: institutional data
Institutional activity
institutional ownership data for VOR is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$13
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive